GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide ghrelin receptor agonist that stimulates GH release from the pituitary. It produces robust, dose-dependent GH spikes and is used both in biohacker GH optimization protocols and clinically as a diagnostic test for GH deficiency. Developed in the late 1980s–1990s and returning to Category 1 access under the 2026 RFK reclassification.

How does GHRP-2 compare to ipamorelin?

GHRP-2 produces stronger raw GH pulses than ipamorelin but is less selective — it elevates cortisol and prolactin alongside GH, while ipamorelin was specifically engineered to avoid these secondary effects. For users who want maximum GH response and can manage the cortisol/appetite trade-offs, GHRP-2 is the choice. For users who want the cleanest long-term GH profile, ipamorelin is superior.

What is the CJC-1295 + GHRP-2 stack?

CJC-1295 (no-DAC) stimulates GH release via GHRH receptors. GHRP-2 stimulates GH release via ghrelin receptors. These are independent receptor systems that converge on GH secretion — combining them produces synergistic GH elevation substantially greater than either alone (Bowers et al., JCEM 1990). Standard stack: 100–200 mcg CJC-1295 + 100–150 mcg GHRP-2 injected simultaneously, primarily before bed.

Does GHRP-2 raise cortisol?

Yes — GHSR activation in the pituitary and hypothalamus stimulates ACTH release, which drives cortisol production. This is documented in human studies (Alster et al., JCEM 1993). The elevation is dose-dependent and real. For intermittent protocols (1–3x daily), it is generally within physiological ranges. Long-term daily use with sustained cortisol elevation is a legitimate concern — cycling is appropriate.

COMPOUND LIBRARY·GHRP-2

COMPOUND PROFILE · PEPPERLEDGER

GHRP-2

Type

Synthetic hexapeptide — ghrelin receptor agonist

Class

GHSR agonist — stimulates GH release via ghrelin receptor pathway

Administration

Subcutaneous injection · Intranasal (used but less bioavailable)

Half-life

~15–60 minutes

Most studied use

GH stimulation for body composition and recovery · GH deficiency diagnostic testing

Regulatory status

Not FDA-approved · Returning to Category 1 under 2026 RFK reclassification · Research chemical

Human evidence

Good — multiple human PK/PD studies confirming GH-releasing potency; used in diagnostic testing for GH deficiency

Preclinical evidence

Strong — well-characterized GH-releasing mechanism

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is GHRP-2?

GHRP-2 is one of the original synthetic growth hormone-releasing peptides — developed in the late 1980s and early 1990s as part of a research program to find stable GH secretagogues. It activates the ghrelin receptor (GHSR) on pituitary somatotrophs to stimulate GH release, producing one of the strongest acute GH responses of any secretagogue in the class. It's also used clinically as a diagnostic tool — the GHRP-2 stimulation test is a validated diagnostic test used in endocrinology to assess pituitary GH reserve.

GHRP-2's defining characteristic is potency. It produces robust, reliable GH spikes — peak GH elevations consistently among the highest of any GH secretagogue tested in humans. The trade-off is selectivity: like GHRP-6 and MK-677, GHRP-2 activates ghrelin pathways broadly, producing meaningful cortisol and prolactin elevation alongside GH. Ipamorelin was specifically engineered to avoid these secondary effects — GHRP-2 was not.

In biohacker communities, GHRP-2 is typically discussed as part of a CJC-1295 + GHRP-2 stack — the dual-receptor approach combining GHRH receptor stimulation (CJC-1295) with ghrelin receptor stimulation (GHRP-2) for synergistic GH elevation. Many biohackers who want maximal GH elevation prefer GHRP-2 over ipamorelin for this stack, accepting the cortisol/prolactin trade-off in exchange for stronger GH pulses.

How it works

GHSR Agonism and GH Release

GHRP-2 binds the ghrelin receptor (GHS-R1a) on anterior pituitary somatotroph cells, activating intracellular calcium signaling and directly stimulating GH granule exocytosis. It also acts at the hypothalamic level to stimulate GHRH release and suppress somatostatin (the GH-inhibiting hormone), creating a triple amplification: pituitary GH release + GHRH stimulation + somatostatin suppression. This combination is why GHRP-2 produces larger GH responses than compounds acting through only one mechanism.

Cortisol and Prolactin Elevation

GHSR activation also stimulates ACTH release, which drives cortisol from the adrenal glands, and prolactin release from lactotroph cells. These effects are dose-dependent and real — documented in human studies. For short-term, intermittent protocols, the cortisol effect is generally manageable. For long-term daily use, sustained cortisol elevation is a legitimate concern. Cycling protocols and monitoring are appropriate for extended use.

The CJC-1295 + GHRP-2 Synergy

CJC-1295 (no-DAC) stimulates GH release through GHRH receptors. GHRP-2 stimulates GH release through ghrelin receptors. These are independent receptor systems converging on GH secretion through different intracellular pathways. Combining them produces synergistic GH elevation — substantially greater than either alone (Bowers et al., 1990). This is the same logic as CJC-1295 + ipamorelin, but GHRP-2 produces stronger raw GH responses.

What the research shows

HUMAN EVIDENCE

STUDYJournal of Clinical Endocrinology & Metabolism · 1993

The GH response to GH-releasing peptide, GHRH, and TRH in acromegaly

Alster DK, Bowers CY, Jaffe CA et al.

In patients with acromegaly, the GH response to a GH-releasing peptide stayed qualitatively normal and did not depend on GHRH — evidence that GHRP-class peptides drive GH release through their own receptor pathway rather than via GHRH. Early human pharmacology behind the GHRP secretagogue approach.

View on PubMed →

STUDYEuropean Journal of Endocrinology · 2007

GHRP-2 test as a reliable diagnostic for adult GH deficiency

Chihara K et al.

A single 100 µg intravenous dose of GHRP-2 produced a peak GH response within 60 minutes and reliably separated severe adult GH-deficient patients from controls (~1.4 vs ~85 µg/L) with good reproducibility. Validated GHRP-2 as a safe alternative to the insulin tolerance test for diagnosing GH deficiency.

View on PubMed →

STUDYJournal of Clinical Endocrinology & Metabolism · 1990

GH-releasing peptide stimulates GH release in normal men and acts synergistically with GHRH

Bowers CY, Reynolds GA, Thorner MO et al.

In healthy men, a GH-releasing peptide plus GHRH released GH synergistically — more together than either alone — confirming the two act through independent receptors. The mechanistic basis for pairing a GHRP with a GHRH analog like CJC-1295 in a stack.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓Robust GH-releasing potency confirmed in multiple human studies
✓Cortisol and prolactin elevation alongside GH — dose-dependent and documented
✓Synergistic GH response with GHRH — mechanistic basis for CJC + GHRP-2 stack
✓Validated diagnostic tool for GH deficiency (GHRP-2 stimulation test)
✓Category 1 return in 2026 — compounding pharmacy access restored

?UNCERTAIN

?Long-term safety beyond diagnostic use durations
?Whether cortisol elevation with intermittent use is clinically significant long-term
?Optimal dosing and frequency for body composition goals
?Long-term body composition outcomes in controlled trials
?Head-to-head vs. ipamorelin for body composition outcomes

What the community reports

GHRP-2 has a long community track record — one of the older GH secretagogues, used in biohacker and bodybuilding circles since the early 2000s. The CJC-1295 + GHRP-2 stack is one of the most-documented GH optimization protocols in the space.

—Strong, reliable GH spikes — users who measure GH post-injection report consistently high peaks; often described as the most reliably potent secretagogue for raw GH elevation

—Sleep quality improvement — deep sleep enhancement; one of the first effects noticed

—Body composition over months — lean mass support and fat reduction with consistent training; gradual rather than dramatic

—Hunger increase — significant appetite stimulation, especially at higher doses; less pronounced than GHRP-6 but real

—GHRP-2 vs. ipamorelin: GHRP-2 often reported as producing stronger GH spikes with more cortisol and hunger

—GHRP-2 vs. GHRP-6: GHRP-2 described as the middle ground — stronger than ipamorelin, less hunger and cortisol than GHRP-6

Common misconceptions

"GHRP-2 and ipamorelin do the same thing."

REALITY

Both are GHSR agonists, but ipamorelin was specifically engineered for selectivity — minimal cortisol, minimal prolactin, minimal appetite. GHRP-2 is less selective and produces meaningful cortisol and prolactin elevation alongside stronger GH release. The choice is a trade-off: selectivity (ipamorelin) vs. raw GH potency (GHRP-2).

"More GHRP-2 produces linearly more GH."

REALITY

The GH response to GHRP-2 saturates — there's a ceiling above which higher doses don't produce proportionally more GH. The dose-response curve is steep at low doses and flattens significantly above 100–150 mcg in most studies. Stacking with CJC-1295 (different receptor) is more effective for amplifying GH than simply increasing GHRP-2 dose.

"The cortisol elevation is dangerous."

REALITY

The cortisol elevation from GHRP-2 is real and dose-dependent, but for intermittent use (1–3x daily), it's generally within physiological ranges and manageable. Long-term daily use with persistently elevated cortisol is a legitimate concern — cycling and monitoring are appropriate for extended protocols.

COMPARE

Ipamorelin — selective GHSR agonist with minimal cortisol/prolactin; cleaner long-term profile. GHRP-6 — stronger hunger and cortisol than GHRP-2; strongest raw GH of the class. CJC-1295 — the GHRH-receptor stack partner.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI RESEARCHER PREVIEW

I'm running CJC-1295 + GHRP-2. What dose and timing gets the best GH pulse?

For CJC-1295 no-DAC + GHRP-2, the protocol optimization comes down to three variables: dose, timing, and injection conditions. On dose: GHRP-2's GH response saturates above 100–150 mcg — there's no meaningful additional GH above that threshold, but you do get more cortisol and appetite. 100 mcg GHRP-2 is the standard starting point. CJC-1295 no-DAC: 100–200 mcg. These are injected simultaneously — they hit different receptor systems and the synergistic response is best when both are present at the same time. On timing: the strongest GH pulses come when you're in a state of low insulin and low somatostatin. This means: injecting on an empty stomach (wait at least 2 hours after eating, or fast), and avoiding high-carbohydrate or high-fat meals immediately after — both blunt GH. The before-bed injection is the most valuable: it amplifies the endogenous GH pulse that accompanies the onset of slow-wave sleep. Insulin is typically lowest at this time, somatostatin is low, and the pituitary is primed for GH secretion. If you're doing multiple daily injections (which some protocols do), the priority order is: before bed first, then pre-workout second if training in the morning, then morning on waking if doing 3x. The before-workout injection has the additional benefit of the GH pulse coinciding with the exercise-induced GH stimulus. Don't eat for at least 30 minutes post-injection if possible — again, insulin blunts the GH response. What's your current frequency? Once daily at bedtime vs. 2–3x daily produces meaningfully different IGF-1 elevation over an 8-week protocol, and the answer to which is better depends on what you're trying to optimize for.

CONTINUE IN THE APP

Open PepperLedger to build your GHRP-2 stack →

Free to join. No credit card. Ask the Researcher about your GHRP-2 protocol once you're in.

Free to join · No credit card · 23-day Pro trial included